Clinical Trials
Therapeutic trials and clinical studies at Princess Margaret
Accuring Trials
A Study of (225Ac)-FPI-2059 in Adult Participants With Solid Tumours
ClinicalTrials.gov ID NCT05605522Sponsor Fusion Pharmaceuticals Inc.Local PI Rebecca WongConditions This is a first-in-human, Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of -FPI-2059 and -FPI-2058, as well as the pharmacodynamics…
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)
ClinicalTrials.gov ID NCT05477576Sponsor RayzeBio, Inc.Local PI Rebecca WongConditions This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard…
(Ac-225)-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)
linicalTrials.gov ID NCT06229366Sponsor POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyLocal PI Di Maria JiangConditions The primary aim of the phase Ia study is to evaluate the safety and tolerability of -PSMA-62 to determine the maximum tolerated dose…
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare)
ClinicalTrials.gov ID NCT05849298Sponsor Novartis PharmaceuticalsLocal PI Robert HamiltonConditions The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with…
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PSMA-DC)
ClinicalTrials.gov ID NCT05939414Sponsor Novartis PharmaceuticalsLocal PI Andrew McPartlinConditions All participants will be assessed for eligibility and will undergo baseline disease assessments including a mandatory gallium (68Ga) gozetotide (also known as Ga-PSMA-11) or piflufolastat (18F) ( also known asDCFPyL) PET/CT scan…
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
ClinicalTrials.gov ID NCT04333537Sponsor NRG OncologyLocal PI John de Almeida Conditions: PRIMARY OBJECTIVES: I. To determine if patient-reported neck and shoulder function and related quality of life (QOL) at 6 months after surgery using the Neck Dissection Impairment Index (NDII) is…
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
ClinicalTrials.gov ID NCT04333537Sponsor NRG OncologyLocal PI John de Almeida Conditions: PRIMARY OBJECTIVES: I. To determine if patient-reported neck and shoulder function and related quality of life (QOL) at 6 months after surgery using the Neck Dissection Impairment Index (NDII) is…
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer (SELECT)
ClinicalTrials.gov ID NCT05451004Sponsor Canadian Cancer Trials GroupLocal PI John de Almeida Conditions: This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by…
Finished Accrual
Study Evaluating mCRPC Treatment Using PSMA [Lu-177)-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
ClinicalTrials.gov ID NCT04647526Sponsor POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyLocal PI Di Maria JiangConditions The primary objective of the study is to determine the efficacy of -PNT2002 (-PSMA-I&T) versus abiraterone or enzalutamide in delaying radiographic progression…
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
ClinicalTrials.gov ID NCT02743741Sponsor University Health Network, TorontoLocal PI Rebecca Wong Conditions: This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by…
A Phase II Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Prostate specific membrane antigen (PSMA)-avid Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
ClinicalTrials.gov ID NCT03939689Sponsor Progenics Pharmaceuticals, Inc.Local PI Neil Fleshner Conditions: This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared to enzalutamide alone in participants with…
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
ClinicalTrials.gov ID NCT04663997Sponsor Canadian Cancer Trials GroupLocal PI Aaron Hansen & Di Maria Jiang Conditions: The standard or usual treatment for this disease is a chemotherapy drug called docetaxel, given by intravenous every 3 weeks, for up to 12 treatments.…
A Phase 1/ 2 Study of (225Ac)-FPI-1434 Injection
ClinicalTrials.gov ID NCT03746431Sponsor Fusion Pharmaceuticals Inc.Local PI Ale Berlin Conditions: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of -FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours…
Completed Trials
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/ Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
ClinicalTrials.gov ID NCT04467515Sponsor PrecirixLocal PI Rebecca Wong Conditions This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients with…
A Phase 1/ 2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)
ClinicalTrials.gov ID NCT01796171Sponsor Nordic NanovectorLocal PI Richard TsangConditions: Part A of the study was a Phase 1/2a study to assess the safety and preliminary efficacy of different treatment regimens of Betalutin with expansion at the candidate recommended Phase 2 doses.…
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)
ClinicalTrials.gov ID NCT02665065Sponsor Actinium PharmaceuticalsLocal PI Arjun Datt LawConditions SIERRA is a pivotal Phase 3 randomized controlled study of Iomab-B in Relapsed or Refractory AML patients. The SIERRA trial has a primary endpoint of durable Complete Remission (dCR) at six…
Need help? Book a call at a time to suit your schedule
Contact us to learn more about the program or if you'd like to set up a time to discuss further how you can help the program or how the program can help you.